Histopathological Characteristics of a Novel Knock-In Mouse Prostate Cancer Model

Total Page:16

File Type:pdf, Size:1020Kb

Histopathological Characteristics of a Novel Knock-In Mouse Prostate Cancer Model Brazilian Journal of Medical and Biological Research (2006) 39: 759-765 Histopathology of a mouse prostate cancer model 759 ISSN 0100-879X Histopathological characteristics of a novel knock-in mouse prostate cancer model G. Wu1,2*, D. Wang1*, 1Department of Urology, Xijing Hospital, the Fourth Military Medical University, H. Wang1, J. Yuan1 Xi’an, China and J.W. Xuan2 2Department of Surgery, University of Western Ontario, London, Ontario, Canada Abstract Correspondence Prostate cancer is relatively unique to man. There is no naturally Key words G. Wu and H. Wang occurring prostate cancer in the mouse. Pre-clinical studies involve • Prostate cancer model Department of Urology the establishment of a genetically engineered mouse prostate cancer • KIMAP mouse model Xijing Hospital model with features close to those of the human situation. A new • Gleason grading system Fourth Military Medical University knock-in mouse adenocarcinoma prostate (KIMAP) model was estab- • Prostate adenocarcinoma Xi’an 710032 China lished, which showed close-to-human kinetics of tumor development. E-mail: [email protected] and In order to determine if the similar kinetics is associated with hetero- [email protected] geneous tumor architecture similar to the human situation, we utilized a new mouse histological grading system (Gleason analogous grading *These authors contributed equally system) similar to the Gleason human grading system and flow to this study. cytometry DNA analysis to measure and compare the adenocarci- noma of the KIMAP model with human prostate cancer. Sixty KIMAP prostate cancer samples from 60 mice were measured and compared Received July 11, 2005 with human prostate cancer. Flow cytometry DNA analysis was Accepted November 23, 2005 performed on malignant prostate tissues obtained from KIMAP mod- els. Mice with prostate cancer from KIMAP models showed a 53.3% compound histological score rate, which was close to the human clinical average (50%) and showed a significant correlation with age (P = 0.001). Flow cytometry analyses demonstrated that most KIMAP tumor tissues were diploid, analogous to the human situation. The similarities of the KIMAP mouse model with tumors of the human prostate suggest the use of this experimental model to complement studies of human prostate cancer. Introduction and multifocality of the clinical disease. CaP is a heterogeneous disease affecting a het- Prostate cancer (CaP), the most common erogeneous population. As a consequence, it cancer in adults in North America, is rela- has been difficult to study the natural history tively unique to man, with no spontaneously of CaP comprehensively. To circumvent this arising CaP being observed in rodents in problem, researchers have historically ex- nature. It has been difficult to rapidly de- ploited immortalized human CaP cell lines, velop effective treatment strategies in part such as LNCaP and DU-145. However, the because there are so few animal models that usefulness of clonal cell lines in culture is accurately mimic the specific heterogeneity limited by the ability to study the dynamic Braz J Med Biol Res 39(6) 2006 760 G. Wu et al. interactions between the various cellular com- netically engineered PSP-knock-in (KIMAP) partments of the prostate gland. For this model, some modifications were adopted reason, the development of genetically engi- according to the established diagnostic crite- neered mouse CaP models is critical for ria previously reported (19-21). In view of preclinical studies of CaP (1-10). the heterogeneity of the clinical standard for Prostate secretory protein of 94 amino CaP diagnosis, a close-to-human mouse acids (PSP94), also known as ß-microsemi- standard for histological grading and scor- noprotein, like human prostate-specific anti- ing system was established in the present gen (PSA), is one of the most abundantly study. We termed this system the “Gleason expressed secretory proteins in human pros- analogous grading system”. The architec- tatic fluid and semen (11,12). Elevated se- tural patterns of adenocarcinoma observed rum levels of PSA and PSP94 have been were scored according to 5 different histo- identified and used as serum markers for the logical grades: grade 1 (very well-differenti- diagnosis and prognosis of CaP. In contrast ated): single, separate, uniform glands closely to PSA, which has no equivalent in rodents, packed, with definite boundaries; grade 2 PSP94 from humans, primates, pigs, and (well-differentiated): single, separate uni- rodents is conserved, but is also a rapidly form glands loosely packed, with irregular evolving protein (13-16). edges; grade 3 (glands with variable and We have established a new knock-in mouse distorted architecture): single, separate, uni- adenocarcinoma of the prostate (KIMAP) form scattered glands, and smoothly cir- model line at the PSP94 gene locus (17,18). cumscribed papillary/cribriform masses; The new KIMAP model proved to have sev- grade 4 (poorly differentiated): cribriform eral advantages over the traditional transgenic masses with ragged, invading edges and fused models, such as prolonged tumor growth, a glands; grade 5: non-glandular solid, rounded predominance of well- and moderately differ- masses of cells, cribriform architecture with entiated tumors, highly synchronous prostate foci of central necrosis (known as come- cancer development, and highly stable pheno- docarcinoma) and undifferentiated anaplas- type and genotype (18). In the present study, tic carcinomas. Based on the most prevalent we utilized a new mouse histological grading histological grade (“the primary pattern/ system (Gleason analogous grading system) grade”) and the second most prevalent histo- similar to the Gleason human grading system logical pattern (“secondary pattern/grade”), and flow cytometry DNA analysis to measure the new mouse scoring system was derived and compare prostate tissue of the new KIMAP by adding the primary pattern grade number model with human CaP tissue. The present to the secondary grade number. If only one study demonstrates the similarity of this new pattern is seen throughout, the score is de- murine prostate cancer model with human rived by doubling the “grade” number. CaP and suggests that KIMAP could be used as an experimental model together with the Anatomy, identification and breeding of transgenic models. knock-in mice by PCR genotyping Material and Methods All animal experiments were conducted according to standard protocols. All KIMAP Histological characterization and definition mouse breeding lines were established mostly of various grades of prostate cancer in in the CD1 or 129Sv background, and the knock-in mice C57BL6 background was also tested with no strain differences. Genotyping was per- To study tumor development in the ge- formed by fast PCR genotyping as previ- Braz J Med Biol Res 39(6) 2006 Histopathology of a mouse prostate cancer model 761 ously reported (18). The primer pairs used the χ2 test and Mann-Whitney test. for screening germline progenies from chi- meras by PCR genotyping were as previ- Results ously reported (17,18). The prostate along with the male acces- Comparison of KIMAP mouse prostate sory glands, i.e., the ventral and dorsolateral tumors with human prostate tumors by the prostate lobes, seminal vesicles and coagu- Gleason analogous grading system lation gland (or the anterior gland), were dissected out separately as previously de- The gross pathology of a KIMAP mouse scribed and defined (15,17). 52 weeks of age with prolonged CaP devel- opment is shown in Figure 1A. In order to Flow cytometry differentiate the heterogeneity of the archi- tecture of mouse prostate tumor, we estab- Flow cytometry DNA analysis was per- lished a new mouse histological grading sys- formed on malignant prostate tissues obtained tem similar to the human Gleason grading from the KIMAP model (N = 9), which were system. Each KIMAP mouse with CaP (N = either freshly excised or snap frozen in liquid 60) was assigned a combination of a primary nitrogen. Single cell suspensions were pre- histological grade (a dominant grade) and a pared according to the standard clinical proce- secondary grade (the non-dominant grade) dures of our hospital. Prior to analysis, each using the mouse Gleason analogous grading cell suspension was filtered through a nylon mesh to remove any debris and cell aggre- gates. Normal mouse spleen lymphocytes were dissociated and used as a control to establish the normal diploid DNA peak position. All samples were analyzed with an EPICS C flow cytometer (Coulter Electronics, Hialeah, FL, USA). The resultant single nucleus suspen- sion was treated with ribonuclease and stained with 50 g/mL propidium iodide (Beckman Coulter, Inc., Miami, FL, USA). DNA histo- grams were classified as diploid, tetraploid, or aneuploid. DNA aneuploidy was defined by the presence of a tumor population with a definable G0/G1 peak which was distinct from the diploid population. Tetraploidy was de- fined by a peak with a DNA index (ratio of the channel number of the abnormal to the diploid population) of 1.9 to 2.1. DNA proliferation Figure 1. Gross pathology and histological analysis of the knock-in mouse adenocarcinoma was measured by flow cytometry as values of prostate (KIMAP) model by a new mouse Gleason analogous grading system. A, Gross %S (percent S phase) and %S + %G2M (per- pathology of a KIMAP mouse 52 weeks of age after prolonged prostate cancer development cent S phase and G M phase) separately (22). showing a 0.3-g ventral prostate lobe tumor. B, Histological score 5 from a KIMAP mouse at 2 age 30 weeks. Two boxes show histological grade 2 (right) and 3 (left) tumor foci. 25X. C, Histological score 6 (histological grades 3 + 3) for a KIMAP mouse at age 30 weeks. 25X. D, Statistical analysis Histological score 7 (3 + 4) for a KIMAP mouse at age 45 weeks. Right area, grade 3, small acinar infiltrating the stroma. Left area, grade 4 showing cribriform acini. 10X. E, Histological score 9 (4 + 5) for a KIMAP mouse at age 67 weeks.
Recommended publications
  • Gleason Grading and Prognostic Factors in Carcinoma of the Prostate
    Modern Pathology (2004) 17, 292–306 & 2004 USCAP, Inc All rights reserved 0893-3952/04 $25.00 www.modernpathology.org Gleason grading and prognostic factors in carcinoma of the prostate Peter A Humphrey Department of Pathology and Immunology, Washington University School of Medicine, Saint Louis, MO, USA Gleason grade of adenocarcinoma of the prostate is an established prognostic indicator that has stood the test of time. The Gleason grading method was devised in the 1960s and 1970s by Dr Donald F Gleason and members of the Veterans Administration Cooperative Urological Research Group. This grading system is based entirely on the histologic pattern of arrangement of carcinoma cells in H&E-stained sections. Five basic grade patterns are used to generate a histologic score, which can range from 2 to 10. These patterns are illustrated in a standard drawing that can be employed as a guide for recognition of the specific Gleason grades. Increasing Gleason grade is directly related to a number of histopathologic end points, including tumor size, margin status, and pathologic stage. Indeed, models have been developed that allow for pretreatment prediction of pathologic stage based upon needle biopsy Gleason grade, total serum prostate-specific antigen level, and clinical stage. Gleason grade has been linked to a number of clinical end points, including clinical stage, progression to metastatic disease, and survival. Gleason grade is often incorporated into nomograms used to predict response to a specific therapy, such as radiotherapy or surgery. Needle biopsy Gleason grade is routinely used to plan patient management and is also often one of the criteria for eligibility for clinical trials testing new therapies.
    [Show full text]
  • Automated Gleason Scoring and Tumor Quantification in Prostate
    cancers Article Automated Gleason Scoring and Tumor Quantification in Prostate Core Needle Biopsy Images Using Deep Neural Networks and Its Comparison with Pathologist-Based Assessment 1,2, 3, 1,4, 5 5 Han Suk Ryu y, Min-Sun Jin y , Jeong Hwan Park y, Sanghun Lee , Joonyoung Cho , Sangjun Oh 5, Tae-Yeong Kwak 5 , Junwoo Isaac Woo 5, Yechan Mun 5, Sun Woo Kim 5, Soohyun Hwang 6, Su-Jin Shin 7 and Hyeyoon Chang 5,* 1 Department of Pathology, Seoul National University College of Medicine, Seoul 03080, Korea; [email protected] (H.S.R.); [email protected] (J.H.P.) 2 Department of Pathology, Seoul National University Hospital, Seoul 03080, Korea 3 Department of Pathology, Bucheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Bucheon, Gyeonggi-do 14647, Korea; [email protected] 4 Department of Pathology, SMG-SNU Boramae Medical Center, Seoul 07061, Korea 5 Deep Bio Inc., 1201 HanWha BizMetro, 242, Digital-ro, Guro-gu, Seoul 08394, Korea; [email protected] (S.L.); [email protected] (J.C.); [email protected] (S.O.); [email protected] (T.-Y.K.); [email protected] (J.I.W.); [email protected] (Y.M.); [email protected] (S.W.K.) 6 Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea; [email protected] 7 Department of Pathology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul 06273, Korea; [email protected] * Correspondence: [email protected]; Tel.: +82-70-7703-4746; Fax: +82-2-2621-2223 These authors contributed equally to this paper.
    [Show full text]
  • Grading Evolution and Contemporary Prognostic Biomarkers of Clinically Significant Prostate Cancer
    cancers Review Grading Evolution and Contemporary Prognostic Biomarkers of Clinically Significant Prostate Cancer Konrad Sopyllo 1, Andrew M. Erickson 2 and Tuomas Mirtti 1,3,* 1 Research Program in Systems Oncology, Faculty of Medicine, University of Helsinki, 00014 Helsinki, Finland; konrad.sopyllo@helsinki.fi 2 Nuffield Department of Surgical Sciences, University of Oxford, Oxford OX3 9DU, UK; [email protected] 3 Department of Pathology, HUS Diagnostic Centre, Helsinki University Hospital, 00029 Helsinki, Finland * Correspondence: tuomas.mirtti@helsinki.fi Simple Summary: Prostate cancer treatment decisions are based on clinical stage and histological diagnosis, including Gleason grading assessed by a pathologist, in biopsies. Prior to staging and grading, serum or blood prostate-specific antigen (PSA) levels are measured and often trigger diagnostic examinations. However, PSA is best suited as a marker of cancer relapse after initial treatment. In this review, we first narratively describe the evolution of histological grading, the current status of Gleason pattern-based diagnostics and glance into future methodology of risk assessment by histological examination. In the second part, we systematically review the biomarkers that have been shown, independent from clinical characteristics, to correlate with clinically relevant end-points, i.e., occurrence of metastases, disease-specific mortality and overall survival after initial treatment of localized prostate cancer. Abstract: Gleason grading remains the strongest prognostic parameter in localized prostate ade- nocarcinoma. We have here outlined the evolution and contemporary practices in pathological evaluation of prostate tissue samples for Gleason score and Grade group. The state of more observer- Citation: Sopyllo, K.; Erickson, A.M.; Mirtti, T. Grading Evolution and independent grading methods with the aid of artificial intelligence is also reviewed.
    [Show full text]
  • Histologic Carcinoma of the Prostate in Autopsies: Frequency, Origin, Extension, Grading and Terminology Athanase Billis, Carlos A.F
    Clinical Urology Brazilian Journal of Urology Vol. 28 (3): 197-206, May - June, 2002 Official Journal of the Brazilian Society of Urology HISTOLOGIC CARCINOMA OF THE PROSTATE IN AUTOPSIES: FREQUENCY, ORIGIN, EXTENSION, GRADING AND TERMINOLOGY ATHANASE BILLIS, CARLOS A.F. SOUZA, HELENICE PIOVESAN Department of Anatomic Pathology, School of Medicine, State University of Campinas (UNICAMP), Campinas, SP, and Pathology Division, School of Medicine, São Francisco University (USF), Bragança Paulista, SP, Brazil ABSTRACT Objective: To study the prostate carcinoma incidentally found in autopsies. Material and Methods: The prostates from 150 autopsied men over 40 years of age were dissected in transitional and peripheral zones. The microscopic examination included presence or absence of adenocarcinoma, neoplastic extension, evaluated by the number of fragments, and histologic grading, according to the Gleason system. Results: The frequency was 36.66%, being significantly higher in older patients with no predilection to color. From a total of 55 carcinomas, 56.36% were found in both transitional and peripheral zones, 25.45% only in transitional zone and 18.18% only in peripheral zone. All neoplasias found only in the transitional zone or only in the peripheral zone were not extense and had low grade. When found in both zones, the carcinoma was not very extense and had low grade in the transitional zone, but it was extense and with high grade in the peripheral zone. In 14.54%, 80% and 5.45% of the carcinomas, the Gleason score was 2 - 4, 5 - 6 and 7, respectively. Gleason score 2 - 4 was significantly more frequent in younger patients and score 7 in older patients.
    [Show full text]
  • Grading of Prostatic Adenocarcinoma: Current State and Prognostic Implications Jennifer Gordetsky1,2 and Jonathan Epstein3,4*
    Gordetsky and Epstein Diagnostic Pathology (2016) 11:25 DOI 10.1186/s13000-016-0478-2 REVIEW Open Access Grading of prostatic adenocarcinoma: current state and prognostic implications Jennifer Gordetsky1,2 and Jonathan Epstein3,4* Abstract Background: Despite significant changes in the clinical and histologic diagnosis of prostate cancer, the Gleason grading system remains one of the most powerful prognostic predictors in prostate cancer. The correct diagnosis and grading of prostate cancer is crucial for a patient’s prognosis and therapeutic options. However, this system has undergone significant revisions and continues to have deficiencies that can potentially impact patient care. Main Body: We describe the current state of grading prostate cancer, focusing on the current guidelines for the Gleason grading system and recent changes from the 2014 International Society of Urological Pathology Consensus Conference on Gleason Grading of Prostatic Carcinoma. We also explore the limitations of the current Gleason grading system and present a validated alternative to the Gleason score. The new grading system initially described in 2013 in a study from Johns Hopkins Hospital and then validated in a multi-institutional study, includes five distinct Grade Groups based on the modified Gleason score groups. Grade Group 1 = Gleason score ≤6, Grade Group 2 = Gleason score 3 + 4 = 7, Grade Group 3 = Gleason score 4 + 3 = 7, Grade Group 4 = Gleason score 8, Grade Group 5 = Gleason scores 9 and 10. Conclusion: As this new grading system is simpler and more accurately reflects prostate cancer biology, it is recommended by the World Health Organization (WHO) to be used in conjunction with Gleason grading.
    [Show full text]
  • Gleason Scoring System: Nuances in Interpretation
    Gleason Scoring System: Nuances in Interpretation Jasreman Dhillon, MD Assistant Member Anatomic Pathology, GU Moffitt Cancer Center Gleason Grading System • Created by Donald F. Gleason in 1966 • Based solely on the architectural pattern of the tumor • Tumors are assigned a Gleason score based on sum of the two most common grade patterns • Certain aspects of the original Gleason system are interpreted differently in today’s practice • Remarkable that more than 40 years after it’s inception, it remains one of the most powerful prognostic predictors in prostate cancer • Multiple molecular marker studies in serum and tissue have largely failed to improve upon the prognostic power of this system. Gleason Score 1977 2005 Consensus Conference on Gleason Grading of Prostatic Carcinoma • International Society of Urological Pathology (ISUP) in 2005 – Incorporate changes in the reporting of Gleason score in pathology reports that reflect the changing clinical practices – Obtain consensus on how to grade newly described variants of prostatic ca e.g. mucinous carcinoma, ductal carcinoma, foamy gland carcinoma – Pathologists: • Achieve consensus on Gleason grading • Help pathologists adapt the Gleason grading system to current day practice in a more uniform manner Variations in Reporting • Do all pathologists follow ISUP 2005 recommendations • How different pathologists interpret ISUP 2005 recommendations • ISUP 2005 Committee could not come to consensus in certain areas of reporting Interpretation of 2005 ISUP Recommendations by Pathologists • European
    [Show full text]
  • May/June 2012 Topics
    Monthly Journal of Updates and Information MAY/JUNE 2012 WHAT’S NEW: The following information is currently available on the FCDS website. REGISTRATION ONLINE: https://fcds.med.miami.edu/scripts/ FLORIDA ANNUAL CANCER register.pl REPORT: INCIDENCE AND MORTALITY - 2007 You may visit the hotel reservation link FCDS/NAACCR EDITs available on the FCDS registration page Metafile - 12.1B Metafile, (click or copy and paste link listed) or posted 02/06/2012 8:15am, 12.1B Metafile changes, call 1-800-360-4016 and reference the minor changes to Reason The 2012 Florida Cancer Data System group code "FCDS" to get the group rate No Radiation edits. Annual Conference is being held July 26th of $139.00. FCDS/NAACCR th -27 , 2012 at the TradeWinds Island Re- WEBINAR SERIES: sorts in St Pete Beach. The FCRA Annual **Deadline for group rate NAACCR 2011-2012 conference is at the same hotel and pre- reservations is 7/9/2012.** CANCER REGISTRY cedes the FCDS conference. AND SURVEILLANCE WEBINAR SERIES - ICD-10-CM AND CANCER Hotel requires a one-night deposit at SURVEILLANCE, 07/12/2012, TOPICS: reservation time. 48 hours notice for BEING HELD AT 7 NPCR CER & AHRQ Projects cancellation to return your deposit. FLORIDA FACILITIES AND requires registration. Quality Control - Reviews & Exercises For more information contact: Web-based Education & User Bleu Thompson Controlled Facility Profiles Florida Cancer Data System Tumor Consolidation PO Box 016960 (D4-11) Cancer Patient Portal Miami, Florida 33101 [email protected] Unified Case Finding Follow Back 305-243-2635 305-243-4871 (Fax) *Slides/Handouts will be available for printing prior to conference as nothing The Florida Cancer Data System will be distributed at the meeting.* (FCDS) is Florida's statewide, popu- lation-based cancer registry and has been collecting incidence data since 1981.
    [Show full text]
  • Automated Gleason Grading of Prostate Biopsies Using Deep Learning
    Automated Gleason Grading of Prostate Biopsies using Deep Learning Wouter Bulten1,*, Hans Pinckaers1, Hester van Boven2, Robert Vink3, Thomas de Bel1, Bram van Ginneken4, Jeroen van der Laak1, Christina Hulsbergen-van de Kaa3, and Geert Litjens1 1Radboud University Medical Center, Radboud Institute for Health Sciences, Department of Pathology, Nijmegen, The Netherlands 2The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital (NKI-AVL), Department of Pathology, Amsterdam, The Netherlands 3Laboratory of Pathology East Netherlands (LabPON), Hengelo, The Netherlands 4Radboud University Medical Center, Radboud Institute for Health Sciences, Department of Radiology & Nuclear Medicine, Nijmegen, The Netherlands *[email protected] ABSTRACT The Gleason score is the most important prognostic marker for prostate cancer patients but suffers from significant inter- observer variability. We developed a fully automated deep learning system to grade prostate biopsies. The system was developed using 5834 biopsies from 1243 patients. A semi-automatic labeling technique was used to circumvent the need for full manual annotation by pathologists. The developed system achieved a high agreement with the reference standard. In a separate observer experiment, the deep learning system outperformed 10 out of 15 pathologists. The system has the potential to improve prostate cancer prognostics by acting as a first or second reader. Introduction With 1.2 million new prostate cancer cases each year1, a high incidence-to-mortality ratio, and risk of overdiagnosis and overtreatment2,3 , there is a strong need for accurate assessment of patient prognosis. Currently, the Gleason score4, assigned by a pathologist after microscopic examination of cancer morphology, is the most powerful prognostic marker for prostate cancer (PCa) patients.
    [Show full text]
  • EARLY ONLINE RELEASE Note: This Article Was Posted on the Archives Web Site As an Early Online Release
    EARLY ONLINE RELEASE Note: This article was posted on the Archives Web site as an Early Online Release. Early Online Release articles have been peer reviewed, copyedited, and reviewed by the authors. Additional changes or corrections may appear in these articles when they appear in a future print issue of the Archives. Early Online Release articles are citable by using the Digital Object Identifier (DOI), a unique number given to every article. The DOI will typically appear at the end of the abstract. The DOI for this manuscript is doi: 10.5858/arpa.2015-0487-SA The final published version of this manuscript will replace the Early Online Release version at the above DOI once it is available. © 20163 College of American Pathologists Special Article Prostate Cancer Grading A Decade After the 2005 Modified Gleason Grading System Oleksandr N. Kryvenko, MD; Jonathan I. Epstein, MD Since 1966, when Donald Gleason first proposed grading acknowledged the contribution of pathologist John T. prostate cancer based on its histologic architecture, there Geraghty, MD, who described pathologic findings in 9 have been numerous changes in clinical and pathologic autopsies, 6 radical prostatectomies (RPs), and 24 partial practices relating to prostate cancer. Patterns 1 and 2, prostatectomies.2 The author noted that ‘‘the histologic comprising more than 30% of cases in the original character of cancer of the prostate is very variable’’ and publications by Gleason, are no longer reported on biopsy described acinar, scirrhous, and solid patterns of growth. and are rarely diagnosed on radical prostatectomy. Many Interestingly, intraductal spread of carcinoma was also of these cases may even have been mimickers of prostate noted.
    [Show full text]
  • Prostate Cancer Grading, Current Status and New Grading System
    PROSTATE CANCER PATHOLOGY: UPDATES DR. KHALIDA NASIM PATHOLOGY AND LAB MEDICINE WINDSOR REGIONAL HOSPITAL Disclosures • I have nothing to disclose. OBJECTIVES • Reporting of prostate cancer pathology, • Grading of prostate cancer…. Gleason scoring. • Overview of the deficiencies in the old Gleason scoring system. • The new Grade grouping system, its validity and its impact on the clinical practice. • The importance of high Grade PIN and ASAP in a pathology report. INTRODUCTION • Prostate cancer is the most commonly diagnosed male malignancy. • According to the SEER (Surveillance, Epidemiology, and End results) program of the National Cancer Institute (NCI), the 2017 data shows an estimated 161,360 new cases in the United States, representing 9.6% of all new cancer cases and 26730 deaths. • Prostate cancer accounts for about one-fifth (21%) of all new cancer cases in men in Canada. (http://www.cancer.ca/en/cancer-information/cancer) INTRODUCTION- CONTD. • The correct diagnosis and grading is crucial for a patient’s prognosis and therapeutic options. • The Gleason grading is the most commonly used histological grading system • Continues to be the single most powerful predictor of prostate cancer prognosis and plays a significant role in clinical management. • Recommended by the World Health Organization. National comprehensive cancer network (NCCN) prostate cancer risk stratification Biopsy Pathological Reporting (Core, Specimen) • In a prostate biopsy case, 10 to 14 cores are generally received. • WRH practice…. 12 cores, submitted in 12 separate site-specific labeled containers. • The reporting of prostate biopsies may be done at core and/or specimen level. • The International Society of Urological Pathology (ISUP) recommends grading at the core level, if the cores are separately identified.
    [Show full text]
  • The Path Way
    THE PATH WAY December, 2015 Volume 6, Issue 4 NF package on the News Center featuring Dr. Carroll’s work and the new national biobank. We also have a piece about our patient Tori and how NF Steven L. Carroll, M.D., Ph.D. has affected her life. Here are the links to the two stories and Emma’s nice infographic. www.musc.edu/pr/newscenter/2015/neurofibromatosis-nf.html Inside this issue: www.musc.edu/pr/newscenter/2015/dr-steven-carroll-nf-biobank.html Dr. Steven Carroll Article Links 1-2 Business Office Announcements 2-3 Arrivals and Departures 4 Congratulations & Museum 5 Research Division Update 6 Dr. Laura Spruill’s Article 7-8 Dr. Christine Litwin’s Article 9-10 SAVE THE DATE-Earth Day 10 Faculty Focus - Dr. Schandl 11 2015 Holiday Party Pictures 12-13 Upcoming Meetings 14 This newsletter is made possible from the generous contributions of MUSC's Pathology and Laboratory Medicine Faculty and Staff. The success of this publication is dependent upon this support. Thank you for your interest, time and information. For inquiries, suggestions or submission information please contact Lori Roten ([email protected]). 1 First Year Class Faculty Award Debra Hazen-Martin, Ph.D. — Nominee Second Year Class Faculty Award Nick Batalis, M.D. — Nominee Debra Hazen-Martin, Ph.D. — Nominee Sally Self, M.D.— Nominee CONGRATULATIONS!! PROMOTIONS IN 2015 Jonathan S. Ralston, M.D., promoted to Associate Professor, effective July 1, 2015 Demetri Spyropoulos, Ph.D., promoted to Professor, effective July 1, 2015 Shaoli Sun, M.D., promoted to Clinical Professor, effective July 1, 2015 Julie Woolworth, Ph.D., promoted to Assistant Professor, effective July 1, 2015 Yusheng Zhu, Ph.D., promoted to Professor, effective July 1, 2015 TENURE IN 2016 Hainan Lang, Ph.D., granted Tenure, effective January 1, 2016 Cynthia A.
    [Show full text]
  • Changes in the Gleason Grading System
    3+3=1! Changes in the Gleason Grading System J. Dhillon, MD Assistant member, Anatomic Pathology, GU Gleason Grading System • Dr. Donald Gleason, the Chief of Pathology at the Veteran’s Hospital in Minnesota • Based on a study of 270 men with prostate cancer from 1959 through 1964 • Based on Histologic patterns of the PA • As most cases have two histologic patterns, a score was created that added the two most common grade patterns in the tumor • We have scores ranging from 2 to 10 Gleason Score 1977 2005 Gleason Pattern 4 Gleason Grading System • Significant revisions – 2005, the most current being the 2014 ISUP • It is the single most powerful predictor of prostate cancer prognosis and directs clinical management • Continues to have deficiencies that can potentially impact patient care Gleason Grading System • Gleason’s original data – GS 2-5 comprised 28% – GP 4 (GS 7, 8, 9) comprised 12% • Danneman et al – GS 2-5 comprised 27% in 1998 – GS 2-5 comprised 1% in 2011 – GS 7 comprised 38% in 2011 • Grade scores 2-5 have disappeared from clinical practice • Many former Gleason score 6 tumors are now reclassified as Gleason score 7 in the modified system. Gleason Grading System • Multiple modifications – much more complex than its original version – Confusing for the patients and the clinicians • Gleason 6 is now recommended as the lowest grade to be assigned on prostate biopsy • Counterintuitive in that the Gleason scale ranges from 2 to 10 Gleason Grading System • Modern Gleason score 6 tumors have a more restrictive definition, much better
    [Show full text]